Prophylactic Multi-Subunit Vaccine against Chlamydia trachomatis In Vivo Evaluation in Mice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Hegemann, Johannes H
Guzman, Carlos Alberto
MetadataShow full item record
AbstractChlamydia trachomatis is the most frequent sexually-transmitted disease-causing bacterium. Urogenital serovars of this intracellular pathogen lead to urethritis and cervicitis. Ascending infections result in pelvic inflammatory disease, salpingitis, and oophoritis. One of 200 urogenital infections leads to tubal infertility. Serovars A-C cause trachoma with visual impairment. There is an urgent need for a vaccine. We characterized a new five-component subunit vaccine in a mouse vaccination-lung challenge infection model. Four recombinant Pmp family-members and Ctad1 from C. trachomatis serovar E, all of which participate in adhesion and binding of chlamydial elementary bodies to host cells, were combined with the mucosal adjuvant cyclic-di-adenosine monophosphate. Intranasal application led to a high degree of cross-serovar protection against urogenital and ocular strains of C. trachomatis, which lasted at least five months. Critical evaluated parameters were body weight, clinical score, chlamydial load, a granulocyte marker and the cytokines IFN-γ/TNF-α in lung homogenate. Vaccine antigen-specific antibodies and a mixed Th1/Th2/Th17 T cell response with multi-functional CD4+ and CD8+ T cells correlate with protection. However, serum-transfer did not protect the recipients suggesting that circulating antibodies play only a minor role. In the long run, our new vaccine might help to prevent the feared consequences of human C. trachomatis infections.
CitationVaccines (Basel). 2021 Jun 6;9(6):609. doi: 10.3390/vaccines9060609.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
- <i>Chlamydia trachomatis</i> Cross-Serovar Protection during Experimental Lung Reinfection in Mice.
- Authors: Lanfermann C, Kohn M, Laudeley R, Rheinheimer C, Klos A
- Issue date: 2021 Aug 6
- An optimized, fast-to-perform mouse lung infection model with the human pathogen Chlamydia trachomatis for in vivo screening of antibiotics, vaccine candidates and modified host-pathogen interactions.
- Authors: Dutow P, Wask L, Bothe M, Fehlhaber B, Laudeley R, Rheinheimer C, Yang Z, Zhong G, Glage S, Klos A
- Issue date: 2016 Mar
- Stromal Fibroblasts Drive Host Inflammatory Responses That Are Dependent on Chlamydia trachomatis Strain Type and Likely Influence Disease Outcomes.
- Authors: Jolly AL, Rau S, Chadha AK, Abdulraheem EA, Dean D
- Issue date: 2019 Mar 19
- The Predominant CD4<sup>+</sup> Th1 Cytokine Elicited to Chlamydia trachomatis Infection in Women Is Tumor Necrosis Factor Alpha and Not Interferon Gamma.
- Authors: Jordan SJ, Gupta K, Ogendi BMO, Bakshi RK, Kapil R, Press CG, Sabbaj S, Lee JY, Geisler WM
- Issue date: 2017 Apr
- A Recombinant Chlamydia trachomatis MOMP Vaccine Elicits Cross-serogroup Protection in Mice Against Vaginal Shedding and Infertility.
- Authors: Tifrea DF, Pal S, de la Maza LM
- Issue date: 2020 Jan 2